ELEV vs. GNFT, INMB, OPT, FENC, IPSC, GLUE, CMPX, ABOS, AGEN, and IPHA
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Genfit (GNFT), INmune Bio (INMB), Opthea (OPT), Fennec Pharmaceuticals (FENC), Century Therapeutics (IPSC), Monte Rosa Therapeutics (GLUE), Compass Therapeutics (CMPX), Acumen Pharmaceuticals (ABOS), Agenus (AGEN), and Innate Pharma (IPHA). These companies are all part of the "biological products, except diagnostic" industry.
Elevation Oncology (NASDAQ:ELEV) and Genfit (NASDAQ:GNFT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
Elevation Oncology presently has a consensus price target of $7.40, suggesting a potential upside of 98.39%. Genfit has a consensus price target of $11.00, suggesting a potential upside of 134.04%. Given Genfit's higher probable upside, analysts clearly believe Genfit is more favorable than Elevation Oncology.
Elevation Oncology has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Genfit has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Genfit received 39 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 69.44% of users gave Elevation Oncology an outperform vote while only 68.09% of users gave Genfit an outperform vote.
Genfit has higher revenue and earnings than Elevation Oncology.
Genfit's return on equity of 0.00% beat Elevation Oncology's return on equity.
83.7% of Elevation Oncology shares are held by institutional investors. Comparatively, 2.2% of Genfit shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by company insiders. Comparatively, 4.2% of Genfit shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Genfit had 3 more articles in the media than Elevation Oncology. MarketBeat recorded 4 mentions for Genfit and 1 mentions for Elevation Oncology. Genfit's average media sentiment score of 0.50 beat Elevation Oncology's score of 0.00 indicating that Genfit is being referred to more favorably in the news media.
Summary
Genfit beats Elevation Oncology on 8 of the 13 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
